- Home
- TOUR vs INMB Comparison
TOUR vs INMB Comparison
Compare TOUR & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOUR | INMB |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 64.7M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TOUR | INMB |
|---|---|---|
| Price | $5.20 | $2.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 7.3K | ★ 307.9K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.56 | $1.09 |
| 52 Week High | $7.79 | $2.60 |
Technical Indicators
Market Signals| Indicator | TOUR | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 55.16 |
| Support Level | $4.93 | $2.21 |
| Resistance Level | $5.32 | $2.50 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 83.05 | 32.93 |
Price Performance
Historical ComparisonAbout TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.